Contrast-enhanced computed tomography (CT) of the neck-thorax-abdomen and pelvis, including 3-phase examination of the liver, constitutes the basic imaging for primary neuroendocrine tumor (NET) diagnosis, staging, surveillance, and therapy monitoring. CT characterization of lymph nodes is difficult because of inadequate size criteria (short axis diameter), and bone metastases are often missed. Contrast-enhanced magnetic resonance imaging (MRI) including diffusion-weighted imaging is preferred for the examination of the liver, pancreas, brain and bone. MRI may miss small lung metastases. MRI is less well suited than CT for the examination of extended body areas because of the longer examination procedure. Ultrasonography (US) frequently provides the initial diagnosis of liver metastases and contrast-enhanced US is excellent to characterize liver lesions that remain equivocal on CT/MRI. US is the method of choice to guide the biopsy needle for the histopathological NET diagnosis. US cannot visualize thoracic NET lesions for which CT-guided biopsy therefore is used. Endocopic US is the most sensitive method to diagnose pancreatic NETs, and additionally allows for biopsy. Intraoperative US facilitates lesion detection in the pancreas and liver. Somatostatin receptor imaging should be a part of the tumor staging, preoperative imaging and restaging, for which 68Ga-DOTA-somatostatin analog PET/CT is recommended, which is vastly superior to somatostatin receptor scintigraphy, and facilitates the diagnosis of most types of NET lesions, for example lymph node metastases, bone metastases, liver metastases, peritoneal lesions, and primary small intestinal NETs. 18FDG-PET/CT is better suited for G3 and high G2 NETs, which generally have higher glucose metabolism and less somatostatin receptor expression than low-grade NETs, and additionally provides prognostic information.

Keywords:
Neuroendocrine tumor, Computed tomography, Magnetic resonance imaging, Ultrasound, Positron emission tomography, Scintigraphy, Single photon emission computed tomography, Somatostatin receptor imaging
1.
Sundin A, Vullierme MP, Kaltsas G, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90:167-183.
2.
Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, Vitek P, Sundin A, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009;90:184-189.
3.
Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN, Jager PL: Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006;7:728-734.
4.
Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F, Denecke T, Pavel M, Pascher A, Wiedenmann B, Amthauer H: 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 2011;52:697-704.
5.
Veit-Haibach P, Schiesser M, Soyka J, Strobel K, Schaefer NG, Hesselmann R, Clavien PA, Hany TF: Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component. Eur Radiol 2011;21:256-264.
6.
Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ: 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-518.
7.
Fidler JL, Fletcher JG, Reading CC, Andrews JC, Thompson GB, Grant CS, Service FJ: Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am J Roentgenol 2003;181:775-780.
8.
Ichikawa T, Peterson MS, Federle MP, Baron RL, Haradome H, Kawamori Y, Nawano S, Araki T: Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000;216:163-171.
9.
Gouya H, Vignaux O, Augui J, Dousset B, Palazzo L, Louvel A, Chaussade S, Legmann P: CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 2003;181:987-992.
10.
Procacci C, Carbognin G, Accordini S, Biasiutti C, Bicego E, Romano L, Guarise A, Minniti S, Pagnotta N, Falconi M: Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization. Eur Radiol 2001;11:1175-1183.
11.
Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E: Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Surgery 2011;150:1122-1128.
12.
Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, van Graafeiland BJ, Monetti N, Bombardieri E: Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998;25:1396-1403.
13.
Dahdaleh FS, Lorenzen A, Rajput M, Carr JC, Liao J, Menda Y, O'Dorisio TM, Howe JR: The value of preoperative imaging in small bowel neuroendocrine tumors. Ann Surg Oncol 2013;20:1912-1917.
14.
Kumbasar B, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL: Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom Imaging 2004;29:696-702.
15.
Hubalewska-Dydejczyk A, Fröss-Baron K, Mikołajczak R, Maecke HR, Huszno B, Pach D, Sowa-Staszczak A, Janota B, Szybiński P, Kulig J: 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006;33:1123-1133.
16.
Elias D, Lefevre JH, Duvillard P, Goéré D, Dromain C, Dumont F, Baudin E: Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Ann Surg 2010;251:307-310.
17.
Kim JH, Eun HW, Kim YJ, Lee JM, Han JK, Choi BI: Pancreatic neuroendocrine tumour (PNET): staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol 2016;26:1338-1347.
18.
Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S: (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37:722-727.
19.
Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ: Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214-1221.
20.
Johanssen S, Boivin M, Lochs H, Voderholzer W: The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis. Gastrointest Endosc 2006;63:660-665.
21.
Pilleul F, Penigaud M, Milot L, Saurin JC, Chayvialle JA, Valette PJ: Possible small-bowel neoplasms: contrast-enhanced and water-enhanced multidetector CT enteroclysis. Radiology 2006;241:796-801.
22.
Thomsen HS, Webb J: Contrast Media Safety Issues and ESUR Guidelines, ed 3. Berlin, Springer, 2014.
23.
Lardière-Deguelte S, de Mestier L, Appéré F, Vullierme MP, Zappa M, Hoeffel C, Noaves M, Brixi H, Hentic O, Ruszniewski P, Cadiot G, Panis Y, Kianmanesh R: Toward preoperative classification of lymph-node metastases in patients with small intestine neuroendocrine tumours in the era of intestinal-sparing surgery. Neuroendocrinology 2016;103:552-559.
24.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
25.
Taouli B, Beer AJ, Chenevert T, Collins D, Lehman C, Matos C, Padhani AR, Rosenkrantz AB, Shukla-Dave A, Sigmund E, Tanenbaum L, Thoeny H, Thomassin-Naggara I, Barbieri S, Corcuera-Solano I, Orton M, Partridge SC, Koh DM: Diffusion-weighted imaging outside the brain: consensus statement from an ISMRM-sponsored workshop. J Magn Reson Imaging 2016;44:521-540.
26.
de Mestier L, Dromain C, d'Assignies G, Scoazec JY, Lassau N, Lebtahi R, Brixi H, Mitry E, Guimbaud R, Courbon F, d'Herbomez M, Cadiot G: Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer 2014;21:R105-R120.
27.
Miyazaki K, Orton MR, Davidson RL, d'Arcy JA, Lewington V, Koh TS, Thng CH, Leach MO, Collins DJ, Koh DM: Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response. Radiology 2012;263:139-148.
28.
Termanini B, Gibril F, Reynolds JC, Doppman JI, Chen CC, Stewart CA, Sutliff VE, Jensen RT: Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997;112:335 -347.
29.
Carlson B, Johnson CD, Stephens DH, Ward EM, Kvols LK: MRI of pancreatic islet cell carcinoma. J Comput Assist Tomogr 1993;17:735-740.
30.
Caramella C, Dromain C, Baere T, Boulet B, Schlumberger M, Ducreux ME, Baudin E: Endocrine pancreatic tumours: which are the most useful MRI sequences? Eur Radiol 2010;20:2618-2627.
31.
Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, Neumann R, Haug AR, Jansen N, Nikolaou K, Schramm N, Reiser MF, Rist C: Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging 2013;40:897-907.
32.
Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB: Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 2000;214:483-490.
33.
Brenner R, Metens T, Bali M, Demetter P, Matos C: Pancreatic neuroendocrine tumor: added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection. Eur J Radiol 2012;81:746-749.
34.
Mayerhoefer ME, Ba-Ssalamah A, Weber M, Mitterhauser M, Eidherr H, Wadsak W, Raderer M, Trattnig S, Herneth A, Karanikas G: Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. Eur Radiol 2013;23:1978-1985.
35.
Ceelen F, Theisen D, de Albéniz XG, Auernhammer CJ, Haug AR, D'Anastasi M, Paprottka PM, Rist C, Reiser MF, Sommer WH: Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases? J Magn Reson Imaging 2015;41:361-368.
36.
Schreiter NF, Nogami M, SteffenI, Pape UF, Hamm B, Brenner W, Röttgen R: Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol 2012;22:458-467.
37.
Wulfert S, Kratochwil C, Choyke PL, Afshar-Oromieh A, Mier W, Kauczor HU, Schenk JP, Haberkorn U, Giesel FL: Multimodal imaging for early functional response assessment of (90)Y-/(177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT. Mol Imaging Biol 2014;16:586-594.
38.
Moryoussef F, de Mestier L, Belkebir M, Deguelte-Lardière S, Brixi H, Kianmanesh R, Hoeffel C, Cadiot G: Impact on management of liver and whole-body diffusion-weighted magnetic resonance imaging sequences for neuroendocrine tumors: a pilot study. Neuroendocrinology 2017;104:264-272.
39.
De Robertis R, DOnofrio M, Zamboni G, Tinazzi Martini P, Gobbo S, Capelli P, Butturini G, Girelli R, Ortolani S, Cingarlini S, Pederzoli P, Scarpa A: Pancreatic neuroendocrine neoplasms: clinical value of diffusion-weighted imaging. Neuroendocrinology 2016;103:758-770.
40.
d'Assignies G, Fina P, Bruno O, Vullierme MP, Tubach F, Paradis V, Sauvanet A, Ruszniewski P, Vilgrain V: High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology 2013;268:390-399.
41.
Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duvillard P, Elias D, Schlumberger M, Sigal R, Baudin E: Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005;23:70-78.
42.
Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP: 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med 2014;55:1598-1604.
43.
Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Müller M, Brendle C, Werner MK, Claussen CD, Pfannenberg C: Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging 2013;13:63-72.
44.
Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E: Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging 2015;40:1432-1440.
45.
Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC: Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol 2013;48:273-279.
46.
Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K et al: Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005;92:94-101.
47.
Rodallec M, Vilgrain V, Couvelard A, Rufat P, O'Toole D, Barrau V, Sauvanet A, Ruszniewski P, Menu Y: Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 2006;6:77-85.
48.
D'Assignies G, Couvelard A, Bahrami S, Vullierme M-P, Hammel P, Hentic O, Sauvanet A, Bedossa P, Ruszniewski P, Vilgrain V: Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 2009;250:407-416.
49.
Jang KM, Kim SH, Lee SJ, Choi D: The value of gadoxetic acid-enhanced and diffusion-weighted MRI for prediction of grading of pancreatic neuroendocrine tumors. Acta Radiol 2014;55:140-148.
50.
Wang Y, Zongming E, Chen ZE, Yaghmai V, Nikolaidis P, McCarthy RJ, Merrick L, Miller FH: Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics. J Magn Reson Imaging 2011;33:1071-1079.
51.
Manfredi R, Bonatti M, Mantovani W, Graziani R, Segala D, Capelli P, Butturini G, Mucelli RP: Non-hyperfunctioning neuroendocrine tumours of the pancreas: MR imaging appearance and correlation with their biological behaviour. Eur Radiol 2013;23:3029-3039.
52.
Park HS, Kim SY, Hong SM, Park SH, Lee SS, Byun JH, Kim JH, Kim HJ, Lee MG: Hypervascular solid-appearing serous cystic neoplasms of the pancreas: differential diagnosis with neuroendocrine tumours. Eur Radiol 2016;26:1348-1358.
53.
Jang KM, Kim SH, Lee SJ, Park MJ, Lee MH, Choi D: Differentiation of an intrapancreatic accessory spleen from a small (<3-cm) solid pancreatic tumor: value of diffusion-weighted MR imaging. Radiology 2013;266:159-167.
54.
Kang BK, Kim JH, Byun JH, Lee SS, Kim HJ, Kim SY, Lee MG: Diffusion-weighted MRI: usefulness for differentiating intrapancreatic accessory spleen and small hypervascular neuroendocrine tumor of the pancreas. Acta Radiol 2014;55:1157-1165.
55.
Moletta L, Milanetto AC, Vincenzi V, Alaggio R, Pedrazzoli S, Pasquali C: Pancreatic secondary lesions from renal cell carcinoma. World J Surg 2014;38:3002-3006.
56.
Duran R, Ronot M, Kerbaol A, Van Beers B, Vilgrain V: Hepatic hemangiomas: factors associated with T2 shine-through effect on diffusion-weighted MR sequences. Eur J Radiol 2014;83:468-478.
57.
Dromain C, de Baere T, Baudin E, Galline J, Ducreux M, Boige V, Duvillard P, Laplanche A, Caillet H, Lasser P, Schlumberger M, Sigal R: MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 2003;180:121-128.
58.
Danet IM, Semelka RC, Leonardou P, Braga L, Vaidean G, Woosley JT, Kanematsu M: Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 2003;181:809-817.
59.
Li B, Li Q, Nie W, Liu S: Diagnostic value of whole-body diffusion-weighted magnetic resonance imaging for detection of primary and metastatic malignancies: a meta-analysis. Eur J Radiol 2014;83:338-344.
60.
Kukuk GM, Mürtz P, Träber F, Meyer C, Ullrich J, Gieseke J, Ahmadzadehfar H, Ezziddin S, Schild HH, Willinek WA: Diffusion-weighted imaging with acquisition of three b-values for response evaluation of neuroendocrine liver metastases undergoing selective internal radiotherapy. Eur Radiol 2014;24:267-276.
61.
Galiber AK, Reading CC, Charboneau JW, Sheedy PF 2nd, James EM, Gorman B, Grant CS, van Heerden JA, Telander RL: Localization of pancreatic insulinoma: comparison of pre- and intraoperative US with CT and angiography. Radiology 1988;166:405-408.
62.
Zimmer T, Ziegler K, Bäder M, Fett U, Hamm B, Riecken EO, Wiedenmann B: Localisation of neuroendocrine tumours of the upper gastrointestinal tract. Gut 1994;35:471-475.
63.
Zimmer T, Stölzel U, Bäder M, Koppenhagen K, Hamm B, Buhr H, Riecken EO, Wiedenmann B: Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996;39:562-568.
64.
Pitre J, Soubrane O, Palazzo L, Chapuis Y. Endoscopic ultrasonography for the preoperative localization of insulinomas. Pancreas 1996;13:55-60.
65.
Angeli E, Vanzulli A, Castrucci M, Venturini M, Sironi S, Zerbi A, Di Carlo V, Pozza G, Del Maschio A: Value of abdominal sonography and MR imaging at 0.5 T in preoperative detection of pancreatic insulinoma: a comparison with dynamic CT and angiography. Abdom Imaging 1997;22:295-303.
66.
De Angelis C, Carucci P, Repici A, Rizzetto M: Endosonography in decision making and management of gastrointestinal endocrine tumors. Eur J Ultrasound 1999;10:139-150.
67.
Rösch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV Jr, Yasuda K, Heyder N, Palazzo L, Dancygier H, Schusdziarra V, et al: Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992;326:1721-1726.
68.
Ardengh JC, de Paulo GA, Ferrari AP: EUS-guided FNA in the diagnosis of pancreatic neuroendocrine tumors before surgery. Gastrointest Endosc 2004;60:378-384.
69.
Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM: Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000;95:2271-2277.
70.
Glover JR, Shorvon PJ, Lees WR: Endoscopic ultrasound for localisation of islet cell tumours. Gut 1992;33:108-110.
71.
Zimmer T, Scherübl H, Faiss S, Stölzel U, Riecken EO, Wiedenmann B: Endoscopic ultrasonography of neuroendocrine tumours. Digestion 2000;62(suppl 1):45-50.
72.
Proye C, Malvaux P, Pattou F, Filoche B, Godchaux JM, Maunoury V, Palazzo L, Huglo D, Lefebvre J, Paris JC: Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery 1998;124:1134-1143.
73.
Ruszniewski P, Amouyal P, Amouyal G, Grangé JD, Mignon M, Bouché O, Bernades P: Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995;117:629-635.
74.
Fujimori N, Osoegawa T, Lee L, Tachibana Y, Aso A, Kubo H, Kawabe K, Igarashi H, Nakamura K, Oda Y, Ito T: Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors. Scand J Gastroenterol 2016;51:245-252.
75.
Huai JC, Zhang W, Niu HO, Su ZX, McNamara JJ, Machi J: Localization and surgical treatment of pancreatic insulinomas guided by intraoperative ultrasound. Am J Surg 1998;175:18-21.
76.
Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA: Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025-1026. Arch Surg 2001;136:1020-1025.
77.
Téllez-Ávila FI, Acosta-Villavicencio GY, Chan C, Hernández-Calleros J, Uscanga L, Valdovinos-Andraca F, Ramírez-Luna MÁ: Diagnostic yield of endoscopic ultrasound in patients with hypoglycemia and insulinoma suspected. Endosc Ultrasound 2015;4:52-55.
78.
Pongprasobchai S, Lertwattanarak R, Pausawasdi N, Prachayakul V: Diagnosis and localization of insulinoma in Thai patients: performance of endoscopic ultrasonography compared to computed tomography and magnetic resonance imaging. J Med Assoc Thai 2013;96(suppl 2):S187-S193.
79.
Joseph AJ, Kapoor N, Simon EG, Chacko A, Thomas EM, Eapen A, Abraham DT, Jacob PM, Paul T, Rajaratnam S, Thomas N: Endoscopic ultrasonography - a sensitive tool in the preoperative localization of insulinoma. Endocr Pract 2013;19:602-608.
80.
Varma V, Tariciotti L, Coldham C, Taniere P, Buckels JA, Bramhall SR: Preoperative localisation and surgical management of insulinoma: single centre experience. Dig Surg 2011;28:63-73.
81.
Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, Fernández-del Castillo C: Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 2008;247:165-172.
82.
Sotoudehmanesh R, Hedayat A, Shirazian N, Shahraeeni S, Ainechi S, Zeinali F, Kolahdoozan S: Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine 2007;31:238-241.
83.
Kaczirek K, Ba-Ssalamah A, Schima W, Niederle B: The importance of preoperative localisation procedures in organic hyperinsulinism - experience in 67 patients. Wien Klin Wochenschr 2004;116:373-378.
84.
Ardengh JC, Rosenbaum P, Ganc AJ, Goldenberg A, Lobo EJ, Malheiros CA, Rahal F, Ferrari AP: Role of EUS in the preoperative localization of insulinomas compared with spiral CT. Gastrointest Endosc 2000;51:552-555.
85.
Schumacher B, Lübke HJ, Frieling T, Strohmeyer G, Starke AA: Prospective study on the detection of insulinomas by endoscopic ultrasonography. Endoscopy 1996;28:273-276.
86.
Nakamura Y, Matsushita A, Katsuno A, Yamahatsu K, Sumiyoshi H, Mizuguchi Y, Uchida E: Clinical outcomes of 15 consecutive patients who underwent laparoscopic insulinoma resection: the usefulness of monitoring intraoperative blood insulin during laparoscopic pancreatectomy. Asian J Endosc Surg 2015;8:303-309.
87.
Li W, An L, Liu R, Yao K, Hu M, Zhao G, Tang J, Lv F: Laparoscopic ultrasound enhances diagnosis and localization of insulinoma in pancreatic head and neck for laparoscopic surgery with satisfactory postsurgical outcomes. Ultrasound Med Biol 2011;37:1017-1023.
88.
Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, Fernández-del Castillo C: Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 2008;247:165-172.
89.
Wong M, Isa SH, Zahiah M, Azmi KN: Intraoperative ultrasound with palpation is still superior to intra-arterial calcium stimulation test in localising insulinoma. World J Surg 2007;31:586-592.
90.
Chung JC, Choi SH, Jo SH, Heo JS, Choi DW, Kim YI: Localization and surgical treatment of the pancreatic insulinomas. ANZ J Surg 2006;76:1051-1055.
91.
Grover AC, Skarulis M, Alexander HR, Pingpank JF, Javor ED, Chang R, Shawker T, Gorden P, Cochran C, Libutti SK: A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery 2005;138:1003-1008.
92.
Mork H, Ignee A, Schuessler G, Ott M, Dietrich CF: Analysis of neuroendocrine tumour metastases in the liver using contrast-enhanced ultrasonography. Scand J Gastroenterol 2007;42:652-662.
93.
Wu W, Chen MH, Yin SS, Yan K, Fan ZH, Yang W, Dai Y, Huo L, Li JY: The role of contrast-enhanced sonography of focal liver lesions before percutaneous biopsy. AJR Am J Roentgenol 2006;187:752-761.
94.
Bartolotta TV, Midiri M, Quaia E, Bertolotto M, Galia M, Cademartiri F, Lagalla R: Liver haemangiomas undetermined at grey-scale ultrasound: contrast-enhancement patterns with SonoVue and pulse-inversion US. Eur Radiol 2005;15:685-693.
95.
Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J: The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010;51:875-882.
96.
Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE: The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 2010;252:850-856.
97.
Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, Clement PM, Mortelmans L, Bogaerts K, Haustermans K, Nackaerts K, Van Cutsem E, Verslype C, Verbruggen A, Deroose CM: Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol 2016;26:900-909.
98.
Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB: All five cloned somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 1994;198:605-612.
99.
Hoyer D, Epelbaum J, Feniuk W, et al: Somatostatin receptors; in Girdlestrom D (ed): The IUPHAR Compendium of Receptor Characterization and Classification. London, IUPHAR Media, 2000, pp 354-364.
100.
Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ: Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989;264:949-953.
101.
Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J: Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992;103:1207-1214.
102.
Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue JA: Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med 1997;70:471-479.
103.
Csaba Z, Dournaud P: Cellular biology of somatostatin receptors. Neuropeptides 2001;35:1-23.
104.
Reubi JC: Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 1997;41:63-70.
105.
Reubi JC, Waser B, Schaer JC, Laissue JA: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-846.
106.
Binderup T, Knigge U, Mellon Mogensen A, Palnaes Hansen C, Kjaer A: Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology 2008;87:223-232.
107.
Reubi JC, Waser B, Krenning EP, Markusse HM, Vanhagen M, Laissue JA: Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur J Pharmacol 1994;271:371-378.
108.
Olsen IH, Langer SW, Federspiel BH, Oxbøl J, Loft A, Berthelsen AK, Mortensen J, Oturai P, Knigge U, Kjær A: (68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2. Am J Nucl Med Mol Imaging 2016 28;6:59-72.
109.
Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, Hansen CP, Højgaard L, Kjaer A: Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 2010;51:704-712.
110.
Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I: Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med 2014;55:1811-1817.
111.
Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, Cuggia M, Mesbah H, Clement B, Boucher E, Garin E: High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med 2014;55:1786-1790.
112.
Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A: 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978-985.
113.
Cwikla JB, Mikolajczak R, Pawlak D, Buscombe JR, Nasierowska-Guttmejer A, Bator A, Maecke HR, Walecki J: Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs. J Nucl Med 2008;49:1060-1065.
114.
Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EG, Jager PL: Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol 2009;71:199-213.
115.
Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, Montravers F: 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging 2013;40:943-966.
116.
Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, Nanni C, Rizzello A, Franchi R, Fanti S: Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1431-1438.
117.
Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, Vonguggenberg E, Warwitz B, Virgolini IJ: Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010;54:68-75.
118.
Luo Y, Pan Q, Yao S, Yu M, Wu W, Xue H, Kiesewetter DO, Zhu Z, Li F, Zhao Y, Chen X: Glucagon-like peptide-1 receptor PET/CT with 68Ga-NOTA-exendin-4 for detecting localized insulinoma: a prospective cohort study. J Nucl Med 2016;57:715-720.
119.
Sainz-Esteban A, Olmos R, González-Sagrado M, González ML, Ruiz MÁ, García-Talavera P, Gamazo C, Villanueva JG, Cobo A, de Luis D: Contribution of 111In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours. Nucl Med Commun 2015;36:251-259.
120.
Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Rasmussen P, Elema D, von Benzon E, Højgaard L, Kjaer A: 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med 2015;56:847-854.
121.
Perri M, Erba P, Volterrani D, Lazzeri E, Boni G, Grosso M, Mariani G: Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 2008;52:323-333.
122.
Wong KK, Cahill JM, Frey KA, Avram AM: Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol 2010;17:291-297.
123.
Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C: 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011;52:1864-1870.
124.
Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B: Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med 2014;55:204-210.
125.
Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W: Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol 2014;55:389-398.
126.
Johnbeck CB, Knigge U, Kjær A: PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol 2014;10:2259-2277.
127.
Geijer H, Breimer LH: Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2013;40:1770-1780.
128.
Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V: Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012;42:80-87.
129.
Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB: A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50:1927-1932.
130.
Squires MH 3rd, Volkan Adsay N, Schuster DM, Russell MC, Cardona K, Delman KA, Winer JH, Altinel D, Sarmiento JM, El-Rayes B, Hawk N, Staley CA 3rd, Maithel SK, Kooby DA: Octreoscan versus FDG-PET for neuroendocrine tumor staging: a biological approach. Ann Surg Oncol 2015;22:2295-2301.
131.
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ; European Association of Nuclear Medicine (EANM): FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015;42:328-354.
132.
Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sörensen J, Bergström M, Långström B: In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass. Nucl Med Biol 2010;37:265-275.
133.
Haug AR, Rominger A, Mustafa M, Auernhammer C, Göke B, Schmidt GP, Wängler B, Cumming P, Bartenstein P, Hacker M: Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med 2011;52:1679-1683.
134.
Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, Di Pierro D, Ferrari M, Marengo M, Bergamini C: 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72-79.
135.
Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP 1998;28:1-126.
136.
Gibril F, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J, Doppman JL, Jensen RT: Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999;40:539-553.
137.
Castellucci P, Pou Ucha J, Fuccio C, Rubello D, Ambrosini V, Montini GC, Pettinato V, Malizia C, Lodi F, Fanti S: Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med 2011;52:886-890.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.